FORESIGHT AUTONOMOUS-SP ADR (FRSX)

US3455232039 - ADR

2.41  +0.7 (+40.94%)

After market: 2.32 -0.09 (-3.73%)

Fundamental Rating

2

Overall FRSX gets a fundamental rating of 2 out of 10. We evaluated FRSX against 82 industry peers in the Automobile Components industry. FRSX has a great financial health rating, but its profitability evaluates not so good. FRSX has a expensive valuation and it also scores bad on growth.



1

1. Profitability

1.1 Basic Checks

FRSX had negative earnings in the past year.
FRSX had a negative operating cash flow in the past year.
In the past 5 years FRSX always reported negative net income.
FRSX had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

The Return On Assets of FRSX (-99.18%) is worse than 98.78% of its industry peers.
FRSX's Return On Equity of -131.36% is on the low side compared to the rest of the industry. FRSX is outperformed by 90.24% of its industry peers.
Industry RankSector Rank
ROA -99.18%
ROE -131.36%
ROIC N/A
ROA(3y)-63.12%
ROA(5y)-60%
ROE(3y)-75.73%
ROE(5y)-70.94%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

FRSX has a better Gross Margin (71.23%) than 100.00% of its industry peers.
FRSX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 71.23%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

7

2. Health

2.1 Basic Checks

FRSX does not have a ROIC to compare to the WACC, probably because it is not profitable.
FRSX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for FRSX has been increased compared to 5 years ago.
There is no outstanding debt for FRSX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

FRSX has an Altman-Z score of -6.27. This is a bad value and indicates that FRSX is not financially healthy and even has some risk of bankruptcy.
FRSX has a Altman-Z score of -6.27. This is amonst the worse of the industry: FRSX underperforms 93.90% of its industry peers.
FRSX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -6.27
ROIC/WACCN/A
WACC9.36%

2.3 Liquidity

FRSX has a Current Ratio of 7.52. This indicates that FRSX is financially healthy and has no problem in meeting its short term obligations.
FRSX has a Current ratio of 7.52. This is amongst the best in the industry. FRSX outperforms 97.56% of its industry peers.
A Quick Ratio of 7.52 indicates that FRSX has no problem at all paying its short term obligations.
FRSX has a Quick ratio of 7.52. This is amongst the best in the industry. FRSX outperforms 97.56% of its industry peers.
Industry RankSector Rank
Current Ratio 7.52
Quick Ratio 7.52

0

3. Growth

3.1 Past

FRSX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 17.26%, which is quite good.
Looking at the last year, FRSX shows a decrease in Revenue. The Revenue has decreased by -9.64% in the last year.
EPS 1Y (TTM)17.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%78.57%
Revenue 1Y (TTM)-9.64%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%83.64%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for FRSX. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

No dividends for FRSX!.
Industry RankSector Rank
Dividend Yield N/A

FORESIGHT AUTONOMOUS-SP ADR

NASDAQ:FRSX (12/24/2024, 8:14:51 PM)

After market: 2.32 -0.09 (-3.73%)

2.41

+0.7 (+40.94%)

Chartmill FA Rating
GICS SectorConsumer Discretionary
GICS IndustryGroupAutomobiles & Components
GICS IndustryAutomobile Components
Earnings (Last)11-25 2022-11-25/bmo
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner Change-8.46%
Ins Owners0.16%
Ins Owner ChangeN/A
Market Cap36.94M
Analysts82.86
Price TargetN/A
Short Float %0.05%
Short Ratio1.04
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 74.32
P/FCF N/A
P/OCF N/A
P/B 2.64
P/tB 2.64
EV/EBITDA N/A
EPS(TTM)-1.86
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.85
FCFYN/A
OCF(TTM)-0.85
OCFYN/A
SpS0.03
BVpS0.91
TBVpS0.91
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -99.18%
ROE -131.36%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 71.23%
FCFM N/A
ROA(3y)-63.12%
ROA(5y)-60%
ROE(3y)-75.73%
ROE(5y)-70.94%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 19.25%
Cap/Sales 10.26%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.52
Quick Ratio 7.52
Altman-Z -6.27
F-Score4
WACC9.36%
ROIC/WACCN/A
Cap/Depr(3y)112.84%
Cap/Depr(5y)79.6%
Cap/Sales(3y)92.56%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)17.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%78.57%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-9.64%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%83.64%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y6.67%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y15.84%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y13.98%
OCF growth 3YN/A
OCF growth 5YN/A